慢性淋巴细胞白血病中克隆性造血的景观与演化
该研究分析了620例慢性淋巴细胞白血病(CLL)患者(来自CLL12和CLL14试验),采用纠错二代测序(VAF阈值0.5%)检测克隆性造血(CH)。中位随访76.1个月,中位年龄68岁,CH检出率58.2%,最常见累及DNMT3A、TET2、TP53和ASXL1。纵向分析显示多数CH克隆持续存在,部分患者出现新发突变,且不同治疗暴露可筛选特定基因突变;
要点
- CLL患者CH检出率58.2%,常见基因DNMT3A、TET2、TP53、ASXL1。
- 不同治疗可筛选特定CH突变:Ven-Obi暴露出现BAX/U2AF1,Clb-Obi出现PPM1D。
- 大CH克隆(VAF>10%)在安慰剂和Clb-Obi组与不良生存相关,靶向治疗组无预后影响。
核心结论
- CLL患者中CH高发,且不同治疗对CH克隆有基因特异性选择作用。
- 大CH克隆(VAF>10%)在传统治疗(安慰剂或Clb-Obi)中与不良生存独立相关,但在靶向治疗中无预后影响。
- CH与中性粒细胞减少相关,所有Richter转化患者(n=11)均检出CH。
研究设计与样本
- 研究纳入620例CLL患者,来自CLL12(伊布替尼 vs 安慰剂)和CLL14(Ven-Obi vs Clb-Obi)两项试验。
- 采用纠错二代测序检测CH,VAF阈值0.5%;中位随访76.1个月,中位年龄68岁。
主要发现
- CH检出率为58.2%,最常见累及DNMT3A、TET2、TP53和ASXL1。
- CLL14纵向分析显示多数CH克隆持续存在,超过半数患者检出额外CH突变。
- Ven-Obi暴露期间出现BAX和U2AF1突变CH,Clb-Obi暴露期间出现PPM1D突变CH。
- 克隆适应度分析显示治疗期间CH克隆加速扩增,治疗后生长减慢。
- 体外实验显示携带BAX突变的CD34+造血干/祖细胞存活增强、凋亡减少。
关键数值与推荐
- CH检测VAF阈值为0.5%。
- 大CH克隆定义为VAF>10%。
临床怎么用
- CLL患者应关注CH状态,尤其是大克隆(VAF>10%)在接受传统治疗时可能提示不良预后。
- 靶向治疗(伊布替尼或Ven-Obi)可能削弱CH的不良预后影响,治疗选择时可参考CH特征。
- CH与中性粒细胞减少相关,监测血细胞减少时需考虑CH因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukemia (CLL) and clonal hematopoiesis (CH) both commonly occur in older individuals. To characterize CH in CLL, 620 patients were analyzed (CLL12 [ibrutinib vs placebo] and CLL14 [venetoclax-obinutuzumab (Ven-Obi) vs chlorambucil-obinutuzumab (Clb-Obi)]) using error-corrected next-generation sequencing with a variant allele frequency (VAF) threshold of 0.5%. Median follow-up was 76.1 months, and median age was 68 years. CH was detected in 58.2% of patients, most commonly affecting DNMT3A, TET2, TP53, and ASXL1. Longitudinal analysis in CLL14 revealed persistence of the majority of CH clones during follow-up, whereas in more than half of the patients, additional CH mutations were detected. BAX- and U2AF1-mutated CH emerged during Ven-Obi exposure, and PPM1D-mutated CH emerged during Clb-Obi exposure, highlighting treatment gene-specific selection. Clonal fitness analyses revealed accelerated CH clone expansion during therapy, followed by slower growth after treatment. In vitro, genetically modified CD34+ hematopoietic stem/progenitor cells harboring BAX mutations showed enhanced survival and decreased apoptosis. CH was associated with neutropenia, and all patients with Richter transformation (RT; n = 11) had CH. Whole-exome sequencing delineated the contribution of CH mutations in 2 of 4 investigated patients with RT. Large CH clone size (>10% VAF) was independently associated with shorter overall survival with placebo (P = .049) and shorter progression-free survival with Clb-Obi after adjusting for age, immunoglobulin heavy chain variable status, and del(17p). In contrast, CH had no prognostic impact in patients receiving targeted therapies. This study demonstrates the high prevalence of CH, highlights its differential impact across CLL therapies, and underscores its adverse influence on patient outcomes.
引用
- Al-Sawaf O, Locher BN, Christen F, et al. The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia. Blood. 2026. PMID: 41528026. doi:10.1182/blood.2025029905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。